Heinz-Josef Lenz

List of Publications by Year
in descending order

235 papers	24,254 citations	16451 64 h-index	7950 149 g-index
236 all docs	236 docs citations	236 times ranked	26532 citing authors

#	Article	IF	Citations
1	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. Journal of the National Cancer Institute, 2022, 114, 271-279.	6.3	27
2	First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. Journal of Clinical Oncology, 2022, 40, 161-170.	1.6	283
3	Reprogramming CBX8-PRC1 function with a positive allosteric modulator. Cell Chemical Biology, 2022, 29, 555-571.e11.	5.2	12
4	Association of Homologous Recombinationâ€"DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers. Molecular Cancer Therapeutics, 2022, 21, 227-236.	4.1	4
5	Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. Oncogene, 2022, 41, 260-267.	5.9	7
6	Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancerÂâ‰¥ 70 years. European Journal of Cancer, 2022, 163, 1-15.	2.8	6
7	Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer. Clinical Cancer Research, 2022, 28, 1863-1870.	7.0	16
8	Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). Clinical Cancer Research, 2022, 28, 2779-2788.	7.0	11
9	Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab. Clinical Cancer Research, 2022, 28, 1690-1700.	7.0	7
10	Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. Oncogene, 2022, 41, 3455-3460.	5.9	19
11	Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?. British Journal of Cancer, 2022, 127, 957-967.	6.4	6
12	Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials. European Journal of Cancer, 2022, 172, 22-30.	2.8	3
13	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2021, 5, pkaa074.	2.9	6
14	Clinical Validation of a Machine-learningâ€"derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Clinical Cancer Research, 2021, 27, 1174-1183.	7.0	28
15	Humanâ€specific polymorphic pseudogenization of SIGLEC12 protects against advanced cancer progression. FASEB BioAdvances, 2021, 3, 69-82.	2.4	14
16	Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. Clinical Colorectal Cancer, 2021, 20, 84-95.e8.	2.3	15
17	Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Clinical Cancer Research, 2021, 27, 267-275.	7.0	13
18	Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. Clinical Cancer Research, 2021, 27, 2723-2733.	7.0	33

#	Article	IF	Citations
19	Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. Pharmacogenomics Journal, 2021, 21, 285-295.	2.0	3
20	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. Molecular Cancer Therapeutics, 2021, 20, 1153-1160.	4.1	1
21	BRAFV600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. Journal of the National Cancer Institute, 2021, 113, 1386-1395.	6.3	17
22	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. Clinical Cancer Research, 2021, 27, 3234-3242.	7.0	24
23	Clocking cancer: the circadian clock as a target in cancer therapy. Oncogene, 2021, 40, 3187-3200.	5.9	41
24	Molecular Determinants of Gastrointestinal Cancers. Advances in Oncology, 2021, 1, 311-325.	0.2	0
25	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. Scientific Reports, 2021, 11, 12191.	3.3	3
26	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. European Journal of Cancer, 2021, 150, 133-142.	2.8	1
27	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. Journal of the National Cancer Institute, 2021, 113, 1705-1713.	6.3	12
28	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. Oncogene, 2021, 40, 4894-4905.	5.9	19
29	Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RASâ€"MAPK pathway and TP53 as potential predictors of immunotherapy efficacy. Annals of Oncology, 2021, 32, 906-916.	1.2	15
30	Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients. Cancer Genomics and Proteomics, 2021, 18, 317-324.	2.0	4
31	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. Npj Precision Oncology, 2021, 5, 95.	5.4	9
32	Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer. British Journal of Cancer, 2021, , .	6.4	1
33	Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. Pharmacogenetics and Genomics, 2021, 31, 10-16.	1.5	2
34	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). JNCI Cancer Spectrum, 2020, 4, pkz078.	2.9	22
35	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2020, 4, pkaa024.	2.9	8
36	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. PLoS ONE, 2020, 15, e0239439.	2.5	5

#	Article	IF	Citations
37	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. Molecular Cancer Therapeutics, 2020, 19, 2634-2640.	4.1	14
38	Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer. Oncologist, 2020, 25, e1879-e1885.	3.7	2
39	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. , 2020, 8, e001714.		23
40	The structure-function relationship of oncogenic LMTK3. Science Advances, 2020, 6, .	10.3	18
41	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Clinical Cancer Research, 2020, 26, 5943-5951.	7.0	55
42	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. , 2020, 8, e000404.		29
43	WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. Cancers, 2020, 12, 1319.	3.7	10
44	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. Scientific Reports, 2020, 10, 9778.	3.3	5
45	Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases. British Journal of Cancer, 2020, 122, 1518-1524.	6.4	31
46	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€"Anal Task Forces whitepaper. Nature Reviews Clinical Oncology, 2020, 17, 757-770.	27.6	218
47	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. Cancers, 2020, 12, 1742.	3.7	4
48	Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. Cancer Science, 2020, 111, 441-450.	3.9	8
49	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. European Journal of Cancer, 2020, 131, 89-97.	2.8	9
50	Title is missing!. , 2020, 15, e0239439.		0
51	Title is missing!. , 2020, 15, e0239439.		0
52	Title is missing!. , 2020, 15, e0239439.		0
53	Title is missing!. , 2020, 15, e0239439.		0
54	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. Journal of the National Cancer Institute, 2019, 111, 146-157.	6.3	129

#	Article	IF	Citations
55	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. Oncologist, 2019, 24, 319-326.	3.7	29
56	Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. EBioMedicine, 2019, 45, 139-154.	6.1	36
57	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncology, The, 2019, 20, 1070-1082.	10.7	169
58	What Should We Do Better? Lessons from Negative Results of a Biomarker Validation Study. Journal of the National Cancer Institute, 2019, 111, 754-756.	6.3	0
59	Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treatment Reviews, 2019, 81, 101912.	7.7	109
60	Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses. Clinical Colorectal Cancer, 2019, 18, 269-279.e5.	2.3	4
61	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. Clinical Cancer Research, 2019, 25, 3096-3103.	7.0	65
62	Quantitative evidence for early metastatic seeding in colorectal cancer. Nature Genetics, 2019, 51, 1113-1122.	21.4	315
63	The current state of molecular testing in the treatment of patients with solid tumors, 2019. Ca-A Cancer Journal for Clinicians, 2019, 69, 305-343.	329.8	203
64	Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). Journal of Clinical Oncology, 2019, 37, 1876-1885.	1.6	169
65	The safety and efficacy of trifluridineâ€"tipiracil for metastatic colorectal cancer: A pharmacy perspective. American Journal of Health-System Pharmacy, 2019, 76, 339-348.	1.0	7
66	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. European Journal of Cancer, 2019, 111, 138-147.	2.8	4
67	A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors. International Journal of Cancer, 2019, 145, 2450-2458.	5.1	5
68	Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. Journal of Clinical Oncology, 2019, 37, 1217-1227.	1.6	234
69	MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer. Clinical Cancer Research, 2019, 25, 2988-2995.	7.0	42
70	Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. European Journal of Cancer, 2019, 107, 100-114.	2.8	12
71	Genetic variants in CCL5 and CCR5 genes and serum VEGFâ€A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. International Journal of Cancer, 2019, 144, 2567-2577.	5.1	8
72	Safety and Tolerability of c-MET Inhibitors in Cancer. Drug Safety, 2019, 42, 211-233.	3.2	76

#	Article	IF	Citations
73	Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.. Journal of Clinical Oncology, 2019, 37, 635-635.	1.6	31
74	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Molecular Cancer Research, 2018, 16, 805-812.	3.4	169
75	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Clinical Colorectal Cancer, 2018, 17, e471-e488.	2.3	12
76	Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treatment Reviews, 2018, 66, 15-22.	7.7	149
77	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Review of Anticancer Therapy, 2018, 18, 251-266.	2.4	41
78	The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. European Journal of Cancer, 2018, 90, 63-72.	2.8	69
79	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Handâ€"Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Clinical Colorectal Cancer, 2018, 17, e395-e414.	2.3	25
80	A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. British Journal of Cancer, 2018, 118, 938-946.	6.4	29
81	Biomarker-driven and molecular targeted therapies for colorectal cancers. Seminars in Oncology, 2018, 45, 124-132.	2.2	9
82	CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation â€" A target for novel cancer therapy. Cancer Treatment Reviews, 2018, 63, 40-47.	7.7	867
83	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Clinical Cancer Research, 2018, 24, 784-793.	7.0	23
84	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repairâ€"Deficient/Microsatellite Instabilityâ€"High Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2018, 36, 773-779.	1.6	1,525
85	Management of Advanced Small Bowel Cancer. Current Treatment Options in Oncology, 2018, 19, 69.	3.0	25
86	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. British Journal of Cancer, 2018, 119, 1451-1455.	6.4	19
87	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. Pharmacogenomics Journal, 2018, 18, 623-632.	2.0	8
88	Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. Cancer Cell International, 2018, 18, 99.	4.1	48
89	Differentiation Therapy Targeting the Î²-Catenin/CBP Interaction in Pancreatic Cancer. Cancers, 2018, 10, 95.	3.7	39
90	Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. Oncologist, 2018, 23, 1319-1327.	3.7	131

#	Article	IF	Citations
91	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS ONE, 2018, 13, e0193640.	2.5	5
92	Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study. Clinical Colorectal Cancer, 2018, 17, 215-222.e3.	2.3	4
93	Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. Journal of Clinical Oncology, 2018, 36, 3576-3576.	1.6	2
94	Matrix metalloproteinase-related gene polymorphisms to predict efficacy of regorafenib in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 692-692.	1.6	1
95	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. Journal of Cancer Metastasis and Treatment, 2018, 4, 12.	0.8	5
96	Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clinical Advances in Hematology and Oncology, 2018, 16, 735-745.	0.3	59
97	What We Know About Stage II and III Colon Cancer: Itâ€™s Still Not Enough. Targeted Oncology, 2017, 12, 265-275.	3.6	25
98	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 2392.	7.4	670
99	Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. International Journal of Cancer, 2017, 141, 1222-1230.	5.1	21
100	Single nucleotide polymorphisms in the IGFâ€IRS pathway are associated with outcome in mCRC patients enrolled in the FIREâ€3 trial. International Journal of Cancer, 2017, 141, 383-392.	5.1	10
101	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. European Journal of Cancer, 2017, 77, 13-20.	2.8	19
102	Potential role of polymorphisms in the transporter genes ENT1 and MATE1 / OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. European Journal of Cancer, 2017, 86, 197-206.	2.8	22
103	Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 1161-1169.	2.3	5
104	Colorectal cancer: epigenetic alterations and their clinical implications. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 439-448.	7.4	48
105	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncology, The, 2017, 18, 1182-1191.	10.7	2,058
106	Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatinâ€based chemotherapy in patients with metastatic colorectal cancer. Cancer, 2017, 123, 4506-4514.	4.1	8
107	Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. European Journal of Cancer, 2017, 84, 69-80.	2.8	212
108	Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Annals of Oncology, 2017, 28, 2780-2785.	1.2	28

#	Article	IF	Citations
109	Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. Indian Journal of Surgical Oncology, 2017, 8, 580-590.	0.7	2
110	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer. JAMA Oncology, 2017, 3, 194.	7.1	555
111	Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget, 2017, 8, 86356-86368.	1.8	147
112	Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.. Journal of Clinical Oncology, 2017, 35, 3531-3531.	1.6	26
113	Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).. Journal of Clinical Oncology, 2017, 35, 520-520.	1.6	100
114	Association of genetic variations in genes implicated in the axis with outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus chemotherapy.. Journal of Clinical Oncology, 2017, 35, 3585-3585.	1.6	1
115	The safety of monoclonal antibodies for treatment of colorectal cancer. Expert Opinion on Drug Safety, 2016, 15, 799-808.	2.4	24
116	Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. Expert Review of Clinical Pharmacology, 2016, 9, 1091-1108.	3.1	9
117	Phase II Study of Olaparib (AZDâ€2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. Oncologist, 2016, 21, 172-177.	3.7	58
118	Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. Molecular Cancer Therapeutics, 2016, 15, 2814-2821.	4.1	9
119	A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. Molecular Cancer Therapeutics, 2016, 15, 2251-2258.	4.1	6
120	Molecular Pathways: Cachexia Signalingâ€"A Targeted Approach to Cancer Treatment. Clinical Cancer Research, 2016, 22, 3999-4004.	7.0	85
121	Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. Molecular Cancer Therapeutics, 2016, 15, 1740-1745.	4.1	9
122	A novel antimetabolite: TAS-102 for metastatic colorectal cancer. Expert Review of Clinical Pharmacology, 2016, 9, 355-365.	3.1	11
123	TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. Molecular Cancer Therapeutics, 2016, 15, 1405-1411.	4.1	11
124	Overcoming resistance to anti-EGFR therapy â€" where do we stand?. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 258-259.	17.8	10
125	Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. Critical Reviews in Oncology/Hematology, 2016, 100, 117-126.	4.4	1
126	Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. Clinical Cancer Research, 2016, 22, 3218-3226.	7.0	21

#	Article	IF	Citations
127	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. Journal of Clinical Oncology, 2016, 34, 144-150.	1.6	116
128	Impact of primary (1Âº) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).. Journal of Clinical Oncology, 2016, 34, 3504-3504.	1.6	249
129	Genetic variations associated with cancer cachexia pathways to predict survival in metastatic colorectal cancer (mCRC): Results from FIRE-3 and TRIBE.. Journal of Clinical Oncology, 2016, 34, 3590-3590.	1.6	1
130	MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 493-493.	1.6	15
131	Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. Oncotarget, 2016, 7, 53668-53678.	1.8	26
132	CDX2 as a Prognostic Biomarker in Colon Cancer. New England Journal of Medicine, 2016, 374, 2183.	27.0	5
133	TAS-102, a novel antitumor agent: A review of the mechanism of action. Cancer Treatment Reviews, 2015, 41, 777-783.	7.7	115
134	Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. Cancer, 2015, 121, 1898-1905.	4.1	12
135	Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. Annals of Oncology, 2015, 26, 332-339.	1.2	28
136	Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	385
137	Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 692-700.	1.6	686
138	Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. Clinical Cancer Research, 2015, 21, 1583-1590.	7.0	8
139	Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Molecular Cancer Therapeutics, 2015, 14, 2401-2408.	4.1	25
140	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncology, The, 2015, 16, 937-948.	10.7	286
141	The Molecular Taxonomy of Colorectal Cancer: Whatâ€™s New?. Current Colorectal Cancer Reports, 2015, 11, 118-124.	0.5	2
142	Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. New England Journal of Medicine, 2015, 372, 1909-1919.	27.0	1,027
143	Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases. Annals of Oncology, 2015, 26, 1728-1733.	1.2	8
144	Molecular Classification of Gastric Adenocarcinoma: Translating New Insights from The Cancer Genome Atlas Research Network. Current Treatment Options in Oncology, 2015, 16, 17.	3.0	53

#	Article	IF	Citations
145	Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer. Pharmacogenetics and Genomics, 2015, 25, 30-37.	1.5	12
146	Pharmacogenomics of fluorouracil-based chemotherapy toxicity. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 811-821.	3.3	43
147	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. Molecular Cancer Therapeutics, 2015, 14, 2374-2381.	4.1	4
148	Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor. Clinical Cancer Research, 2015, 21, 5002-5007.	7.0	61
149	Predictive and Prognostic Markers in the Treatment of Metastatic Colorectal Cancer (mCRC). Hematology/Oncology Clinics of North America, 2015, 29, 43-60.	2.2	24
150	Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.. Journal of Clinical Oncology, 2015, 33, 3558-3558.	1.6	15
151	LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.. Journal of Clinical Oncology, 2015, 33, TPS3625-TPS3625.	1.6	1
152	Panitumumab: leading to better overall survival in metastatic colorectal cancer?. Expert Opinion on Biological Therapy, 2014, 14, 535-548.	3.1	1
153	Panitumumab safety for treating colorectal cancer. Expert Opinion on Drug Safety, 2014, 13, 1-9.	2.4	9
154	The Kinase LMTK3 Promotes Invasion in Breast Cancer Through GRB2-Mediated Induction of Integrin Î² ₁. Science Signaling, 2014, 7, ra58.	3.6	32
155	Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy. Molecular Cancer Therapeutics, 2014, 13, 528-539.	4.1	37
156	ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer. Cell Reports, 2014, 7, 1940-1955.	6.4	90
157	Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nature Reviews Clinical Oncology, 2014, 11, 282-298.	27.6	312
158	Molecular Pathways: Turning Proteasomal Protein Degradation into a Unique Treatment Approach. Clinical Cancer Research, 2014, 20, 3064-3070.	7.0	13
159	The potential of targeting Wnt/Î²-catenin in colon cancer. Expert Opinion on Therapeutic Targets, 2014, 18, 611-615.	3.4	198
160	So Much Effort, So Little Progress?. Journal of the National Cancer Institute, 2014, 106, .	6.3	5
161	Polymorphisms in folateâ€metabolizing enzymes and response to 5â€fluorouracil among patients with stage II or III rectal cancer (INTâ€0144; SWOG 9304). Cancer, 2014, 120, 3329-3337.	4.1	15
162	CXCR2 inhibition enhances sulindac-mediated suppression of colon cancer development. International Journal of Cancer, 2014, 135, 232-237.	5.1	13

#	Article	IF	Citations
163	Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer. Investigational New Drugs, 2013, 31, 845-857.	2.6	18
164	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, The, 2013, 381, 303-312.	13.7	2,276
165	Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!. Expert Opinion on Pharmacotherapy, 2013, 14, 2203-2220.	1.8	4
166	Markers of Response for the Antiangiogenic Agent Bevacizumab. Journal of Clinical Oncology, 2013, 31, 1219-1230.	1.6	309
167	Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States. Molecular Cancer Therapeutics, 2013, 12, 2261-2272.	4.1	19
168	Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. PLoS ONE, 2013, 8, e66774.	2.5	64
169	A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2013, 31, 2501-2501.	1.6	75
170	Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3514-3514.	1.6	5
171	Influence of Sex on the Survival of Patients With Esophageal Cancer. Journal of Clinical Oncology, 2012, 30, 2265-2272.	1.6	112
172	Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthaseâ€"Targeted Therapies in Nonâ€"Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2012, 11, 616-628.	4.1	44
173	A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas. Clinical Cancer Research, 2012, 18, 1726-1734.	7.0	186
174	Selecting the best targeted agent in firstâ€line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?. Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 528-535.	2.6	2
175	Pancreatic Cancer: Medical Management (Novel Chemotherapeutics). Gastroenterology Clinics of North America, 2012, 41, 189-209.	2.2	31
176	Pharmacogenetic Concerns in Metastatic Colorectal Cancer Therapy. Current Colorectal Cancer Reports, 2012, 8, 263-271.	0.5	1
177	Targeting IL-8 in colorectal cancer. Expert Opinion on Therapeutic Targets, 2012, 16, 491-497.	3.4	72
178	The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models. Molecular Cancer Therapeutics, 2012, 11, 1353-1364.	4.1	97
179	LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Research and Treatment, 2012, 132, 537-544.	2.5	35
180	LMTK3 polymorphism in patients with metastatic colon cancer.. Journal of Clinical Oncology, 2012, 30, 471-471.	1.6	6

#	Article	IF	Citations
181	Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2011, 17, 5783-5792.	7.0	79
182	Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nature Medicine, 2011, 17, 715-719.	30.7	118
183	Interleukinâ€8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. International Journal of Cancer, 2011, 128, 2038-2049.	5.1	379
184	Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma. International Journal of Cancer, 2011, 129, 1096-1104.	5.1	28
185	Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. Pharmacogenomics, 2011, 12, 27-39.	1.3	20
186	The Dual EGFR/HER2 Inhibitor Lapatinib Synergistically Enhances the Antitumor Activity of the Histone Deacetylase Inhibitor Panobinostat in Colorectal Cancer Models. Cancer Research, 2011, 71, 3635-3648.	0.9	78
187	GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients. Annals of Oncology, 2011, 22, 2431-2439.	1.2	25
188	Common Cancer Stem Cell Gene Variants Predict Colon Cancer Recurrence. Clinical Cancer Research, 2011, 17, 6934-6943.	7.0	91
189	A let-7 microRNA-binding site polymorphism in 3â€²-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Annals of Oncology, 2011, 22, 104-109.	1.2	114
190	Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. Journal of Gastrointestinal Oncology, 2011, 2, 77-84.	1.4	151
191	A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemotherapy and Pharmacology, 2010, 65, 979-988.	2.3	52
192	Using The Colon Cancer Multigene Recurrence Score to Determine Risk: Prognostic Milestone or a Step in the Right Direction?. Current Colorectal Cancer Reports, 2010, 6, 183-192.	0.5	0
193	The Colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information. BMC Cancer, 2010, 10, 687.	2.6	7
194	Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients. Clinical Cancer Research, 2010, 16, 5591-5602.	7.0	43
195	Gender Disparities in Metastatic Colorectal Cancer Survival. Clinical Cancer Research, 2009, 15, 6391-6397.	7.0	168
196	Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. International Journal of Cancer, 2009, 125, 463-473.	5.1	68
197	DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Medical Genomics, 2009, 2, 67.	1.5	85
198	Pharmacogenomics and -genetics in colorectal cancer. Advanced Drug Delivery Reviews, 2009, 61, 375-380.	13.7	17

#	Article	IF	Citations
199	Can we predict the response to epidermal growth factor receptor targeted therapy?. Targeted Oncology, 2008, 3, 87-99.	3.6	1
200	Individualization of therapy based on clinical and molecular parameters. Current Colorectal Cancer Reports, 2008, 4, 193-200.	0.5	3
201	First-line combination treatment of colorectal cancer with hepatic metastases: Choosing a targeted agent. Cancer Treatment Reviews, 2008, 34, S3-S7.	7.7	77
202	EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 2311-2319.	1.6	884
203	Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab. Clinical Cancer Research, 2008, 14, 7554-7563.	7.0	179
204	Clinical Determinants of Response to Irinotecan-Based Therapy Derived from Cell Line Models. Clinical Cancer Research, 2008, 14, 6647-6655.	7.0	18
205	Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenetics and Genomics, 2008, 18, 161-168.	1.5	48
206	Management and Preparedness for Infusion and Hypersensitivity Reactions. Oncologist, 2007, 12, 601-609.	3.7	396
207	The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer. Oncologist, 2007, 12, 38-50.	3.7	218
208	Association of Methylenetetrahydrofolate Reductase Gene Polymorphisms and Sex-Specific Survival in Patients With Metastatic Colon Cancer. Journal of Clinical Oncology, 2007, 25, 3726-3731.	1.6	60
209	FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptorâ€"Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab. Journal of Clinical Oncology, 2007, 25, 3712-3718.	1.6	466
210	EGFR, HER2 and VEGF Pathways. Drugs, 2007, 67, 2045-2075.	10.9	125
211	Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumorVEGFAandVEGFRexpression in metastatic CRC patients. Pharmacogenomics, 2007, 8, 1705-1713.	1.3	66
212	Predictive and prognostic markers in colorectal cancer. Gastrointestinal Cancer Research: GCR, 2007, 1, 237-46.	0.7	9
213	Novel approaches to treatment of advanced colorectal cancer with antiâ€EGFR monoclonal antibodies. Annals of Medicine, 2006, 38, 545-551.	3.8	49
214	Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics, 2006, 7, 67-88.	1.3	60
215	Determinants of chemosensitivity in gastric cancer. Current Opinion in Pharmacology, 2006, 6, 337-344.	3.5	41
216	Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. Pharmacogenetics and Genomics, 2006, 16, 555-563.	1.5	21

#	Article	IF	Citations
217	Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenetics and Genomics, 2006, 16, 475-483.	1.5	97
218	Molecular determinants of irinotecan efficacy. International Journal of Cancer, 2006, 119, 2435-2442.	5.1	55
219	Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines. Journal of Clinical Oncology, 2006, 24, 4914-4921.	1.6	504
220	Pharmacogenomics and Colorectal Cancer. Advances in Experimental Medicine and Biology, 2006, 587, 211-231.	1.6	26
221	Molecular Determinants of Cetuximab Efficacy. Journal of Clinical Oncology, 2005, 23, 3536-3544.	1.6	229
222	Gene Polymorphisms of Epidermal Growth Factor Receptor and its Downstream Effector, Interleukin-8, Predict Oxaliplatin Efficacy in Patients with Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2005, 5, 124-131.	2.3	64
223	Epidermal Growth Factor Receptor as a Target for Chemotherapy. Clinical Colorectal Cancer, 2005, 5, S19-S27.	2.3	59
224	Antiangiogenic agents in cancer therapy. Oncology, 2005, 19, 17-25.	0.5	12
225	Capecitabine: the new generation of fluoropyrimidines in colorectal cancer. Expert Review of Anticancer Therapy, 2004, 4, 947-955.	2.4	4
226	Integration of novel agents in the treatment of colorectal cancer. Cancer Chemotherapy and Pharmacology, 2004, 54 Suppl 1, S32-9.	2.3	29
227	The role of proteasome inhibitors in solid tumors. Annals of Medicine, 2004, 36, 296-303.	3.8	30
228	Pharmakogenetik in kolorektalen Karzinomen. Onkologe, 2003, 9, 860-864.	0.7	0
229	Tailoring chemotherapy in advanced colorectal cancer. Current Opinion in Pharmacology, 2003, 3, 378-385.	3.5	26
230	Implications of Genetic Testing in the Management of Colorectal Cancer. Molecular Diagnosis and Therapy, 2003, 3, 73-88.	3.3	13
231	Pharmacogenetic aspects in treatment of colorectal cancer â€“ an update. Pharmacogenomics, 2003, 4, 767-777.	1.3	5
232	A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Research, 2003, 63, 2898-904.	0.9	279
233	Association Between Glutathione S-Transferase P1, T1, and M1 Genetic Polymorphism and Survival of Patients With Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2002, 94, 936-942.	6.3	350
234	Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. International Journal of Colorectal Disease, 2002, 17, 46-49.	2.2	94

#	Article	IF	Citations
235	ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy. Journal of Clinical Oncology, 2001, 19, 4298-4304.	1.6	601